Another week is finished and it's been a disastrous one for research into a potential treatment for Alzheimer’s disease. Two of our top ten stories are, unfortunately, regarding the failure of late-stage candidates for treatment that have been dropped and another where one of the most promising candidates has investors fearing that it, too, may be a dud.
Top Ten most popular articles on Pharmafile.com this week
